Oligomeric Compounds Targeting PTBP1 RNA for Neurogenesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments lack effective options for enhancing neurogenesis in subjects with neurodegenerative diseases associated with neuron loss, particularly for conditions like Parkinson's disease, Huntington's disease, and Alzheimer's disease, where reducing Polypyrimidine Tract Binding Protein 1 (PTBP1) expression in glial cells can potentially replace lost neurons.
Innovation Solution
Development of oligomeric agents, oligomeric compounds, and pharmaceutical compositions that specifically target and reduce PTBP1 RNA or protein levels in cells, utilizing modified oligonucleotides with high complementarity to PTBP1 nucleic acid sequences, to promote neuronal differentiation and regeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for neurodegenerative diseases, then current therapeutic options are limited, but effective neurogenesis enhancement is not achieved
Solution Approach 1:
The patent changes the molecular parameter by introducing oligomeric compounds with specific sequences that bind to PTBP1 mRNA, altering the expression level of PTBP1 protein. This parameter change enables neuronal differentiation from glial cells, providing an effective treatment mechanism for neurodegenerative diseases where conventional therapies have failed.
Solution Approach 2:
The oligomeric compounds act as intermediaries that mediate between the administered therapeutic agent and the target PTBP1 mRNA. These compounds specifically bind to PTBP1 mRNA sequences, reducing PTBP1 protein expression and thereby enabling neuronal differentiation. This intermediary mechanism provides a versatile and effective treatment approach that overcomes the limitations of conventional direct therapies.
2Productivity
If PTBP1 expression is reduced in glial cells, then neuronal differentiation is induced, but the mechanism requires specific molecular targeting
Solution Approach 1:
The patent segments the therapeutic approach by designing oligomeric compounds with specific sequence segments that target different regions of PTBP1 mRNA. The compounds contain nucleotide sequences complementary to specific PTBP1 mRNA regions, enabling precise molecular targeting. This segmentation strategy achieves high productivity in neurogenesis by specifically reducing PTBP1 expression in glial cells without requiring complex multi-component systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compositions effectively reduce PTBP1 expression, facilitating the conversion of glial cells into neurons, thereby potentially alleviating neurodegenerative symptoms and improving motor function and vision by restoring neuronal populations.
Implementation Method 1
the nucleobase sequence of the modified oligonucleotide is at least 80% complementary to the nucleobase sequence of an equal length portion of a PTBP1 nucleic acid
Data Source
AI summary
Provided are oligomeric agents, oligomeric compounds, antisense agents, and pharmaceutical compositions for reducing the amount or activity of PTBP 1 RNA in a cell or animal, and in certain instances reducing the amount of PTBP 1 protein in a cell or animal. Such oligomeric agents, oligomeric compounds, antisense agents, and pharmaceutical compositions are useful to treat neurodegenerative diseases or disorders such as, but not limited to, Parkinson's disease, Huntington's disease, or Alzheimer's disease.